RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Efficacy of Candesartan Cilexetil Alone or in Combination With Amlodipine and Hydrochlorothiazide in Moderate-to-Severe Hypertension
This multicenter study evaluated the efficacy of c and esartan cilexetil , an angiotensin II type 1 receptor antagonist , used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension . After a 2-week , single-blind , placebo run-in period , patients entered a 12-week , open-label , dose-titration period . The c and esartan cilexetil dose was increased from 8 to 16 mg once daily ; amlodipine ( 5 mg once daily ) , hydrochlorothiazide ( 25 mg once daily ) , and additional medication were also added sequentially if necessary . Patients then entered a final 4-week , parallel-group , double-blind , r and omized , placebo-controlled withdrawal period of c and esartan alone .  A total of 216 patients were recruited . After a 2-week run-in period on placebo tablets , mean sitting blood pressure ( BP ) was 175/108 mm Hg . At the end of the 12-week dose-titration/maintenance period , mean sitting BP fell to 141/88 mm Hg . In 67 patients who were r and omized to placebo and had their c and esartan withdrawn , there was a highly significant increase in mean systolic/diastolic BP ( 13/6 mm Hg ) compared with those patients who continued with c and esartan ( ANCOVA , P < 0.0001 ) . In conclusion , c and esartan cilexetil is an effective BP-lowering drug when used alone or in combination with amlodipine or amlodipine plus hydrochlorothiazide in the treatment of moderate-to-severe essential hypertension . The drug was well tolerated throughout the investigation period
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .